Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Herion

Internal Medicine Greenville, SC Doctor of Osteopathy

NPI 1902331275 CMS profile 2922377

701 Grove Rd, 5Th Floor Support Tower, Greenville, SC 29605

Open in the dashboard

General payments

$4,159

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Herion of Greenville, SC is reported in the CMS Open Payments database as having received $4,159 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,798 32
2024 General $977 25
2023 General $325 17
2022 General $46 3
2019 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Herion
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Herion were reported at $2,798. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Herion Internal Medicine median Middle half National median
2019 $13 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $46 $141 $42–$496 $149
2023 $325 $149 $45–$519 $160
2024 $977 $154 $47–$537 $164
2025 $2,798 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,740 24 payments
  2. AstraZeneca Pharmaceuticals LP $313 8 payments
  3. Janssen Biotech, Inc. $221 7 payments
  4. Amgen Inc. $199 10 payments
  5. UCB, Inc. $196 5 payments
  6. Lilly USA, LLC $89 5 payments
  7. Organon LLC $79 4 payments
  8. Fresenius Kabi USA, LLC $65 3 payments
  9. Radius Health, Inc. $48 2 payments
  10. Novartis Pharmaceuticals Corporation $47 2 payments
  11. Other $162 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $2,125 2 payments
  2. Food and Beverage $2,034 76 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI Immunology $2,003 6 payments
  2. RINVOQ $403 16 payments
  3. SAPHNELO $313 8 payments
  4. TREMFYA $221 7 payments
  5. Bimzelx $160 3 payments
  6. SIMPONI ARIA $138 2 payments
  7. TALTZ $89 5 payments
  8. Otezla $67 3 payments
  9. HADLIMA $59 3 payments
  10. SKYRIZI Immunology $56 2 payments
  11. Other $673 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

913

Median for Rheumatology: 1,511

Drug cost

$366,078

Median for Rheumatology: $1,139,948

Branded share of claims

15.7%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 27 $195,797
Enbrel Sureclick Etanercept Brand 12 $87,161
Cimzia (2 Pack) Certolizumab Pegol Brand 12 $64,152
Hydroxychloroquine Sulfate Generic 199 $8,797
Methotrexate Methotrexate Sodium Brand 92 $2,495
Prednisone Generic 233 $1,842
Leflunomide Generic 39 $1,577
Celecoxib Generic 43 $957
Diclofenac Sodium Generic 67 $915
Allopurinol Generic 46 $643

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$1,145,274

Of which drugs: $943,433

Medicare patients

377

Average age 73

Services billed

82,900

269 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 32%
Osteoporosis 29%
Diabetes 25%
Ischemic heart disease 25%
Chronic kidney disease 22%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 43 14,625 $492,403
Injection, golimumab, 1 mg, for intravenous use J1602 Office 36 15,922 $143,000
Injection, tocilizumab, 1 mg J3262 Office 21 24,320 $113,694
Injection, denosumab, 1 mg J0897 Office 33 3,360 $68,556
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 12 13,600 $49,564
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 17 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $137
$137 — —
RINVOQ
  • AbbVie, Inc. $123
$123 — —
SKYRIZI
  • AbbVie, Inc. $56
$56 — —
KRYSTEXXA
  • Amgen Inc. $45
$45 — —
TREMFYA
  • Janssen Biotech, Inc. $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record